“ALTUVIIIO has really exceeded our expectations.”
Considering the switch
It was getting harder to schedule infusions around Paxton’s sports and activities, and he was experiencing more breakthrough bleeding. I was nervous about making a change, but our goal was to protect his body and his joints from bleeds, and the potential for higher factor levels and fewer infusions with ALTUVIIIO was exciting.
Working with Paxton’s doctors
His doctor told us making the switch was the right move, and our hematologist knew Paxton’s physical activity was increasing, thinking of him the day ALTUVIIIO was approved. Paxton’s doctor created a full pharmacokinetic study so we could see the impact on his levels over the first 5 days. Then, she checked in on him every week for the first month. His nurse, care coordinator, and hematologist also took part in the follow-up to the switch.
Expectations vs experience
Making the switch to a brand-new treatment was a bit hectic from an insurance perspective, but the Sanofi Support team was there to help, and we officially switched in April of 2023. Since then, ALTUVIIIO has really exceeded my expectations. Paxton lives with factor levels over 40% several days each week, has not had any breakthrough bleeds, and his Day 7 trough level is 15%.
Things can be better
Sometimes you get used to certain aspects of living with hemophilia, and a lot of patients have a “not broke, don’t fix” mentality—even if it takes 3 infusions per week to fight bleeding. But something doesn’t have to be broken to be improved, and “good enough” isn’t good enough if you're still having breakthrough bleeds. We should always be moving toward higher factor levels, fewer infusions, and a strong safety profile. Don’t let hemophilia steal your joy or your dreams.
This testimonial reflects one patient’s experience and has not been clinically evaluated. It is not intended to imply typical outcomes or substitute for clinical evidence. Paxton and Jenny are promotional speakers compensated by Sanofi and received free product through Sanofi's Support Program.
